-+ 0.00%
-+ 0.00%
-+ 0.00%

Gilead’s Twice-Yearly Lenacapavir Nearly Doubles PrEP Persistence Versus Daily Pill in Trial

PUBT·11/06/2026 17:17:10
Listen to the news
Gilead’s Twice-Yearly Lenacapavir Nearly Doubles PrEP Persistence Versus Daily Pill in Trial
  • Gilead Sciences’ PURPOSE 5 trial found twice-yearly lenacapavir supported more consistent HIV prevention use than daily oral F/TDF over one year.
  • No HIV infections occurred among lenacapavir recipients; one occurred in the F/TDF group.
  • Serious adverse events were uncommon; none were treatment-related. No lenacapavir recipients stopped treatment because of adverse events.
  • Results from the Phase 2 study in the United Kingdom and France will be presented at HIV Glasgow 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261106524470) on November 06, 2026, and is solely responsible for the information contained therein.